The clinical evidence for postbiotics as microbial therapeutics
An optimally operating microbiome supports protective, metabolic, and immune functions, but disruptions produce metabolites and toxins which can be involved in many conditions. Probiotics have the potential to manage these. However, their use in vulnerable people is linked to possible safety concern...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-12-01
|
| Series: | Gut Microbes |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19490976.2022.2117508 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849763443276513280 |
|---|---|
| author | Alexis Mosca Ana Teresa Abreu Y Abreu Kok Ann Gwee Gianluca Ianiro Jan Tack Thi Viet Ha Nguyen Colin Hill |
| author_facet | Alexis Mosca Ana Teresa Abreu Y Abreu Kok Ann Gwee Gianluca Ianiro Jan Tack Thi Viet Ha Nguyen Colin Hill |
| author_sort | Alexis Mosca |
| collection | DOAJ |
| description | An optimally operating microbiome supports protective, metabolic, and immune functions, but disruptions produce metabolites and toxins which can be involved in many conditions. Probiotics have the potential to manage these. However, their use in vulnerable people is linked to possible safety concerns and maintaining their viability is difficult. Interest in postbiotics is therefore increasing. Postbiotics contain inactivated microbial cells or cell components, thus are more stable and exert similar health benefits to probiotics. To review the evidence for the clinical benefits of postbiotics in highly prevalent conditions and consider future potential areas of benefit. There is growing evidence revealing the diverse clinical benefits of postbiotics in many prevalent conditions. Postbiotics could offer a novel therapeutic approach and may be a safer alternative to probiotics. Establishing interaction mechanisms between postbiotics and commensal microorganisms will improve the understanding of potential clinical benefits and may lead to targeted postbiotic therapy. |
| format | Article |
| id | doaj-art-d674ccc8e4d94b728aca0f13fbb8188c |
| institution | DOAJ |
| issn | 1949-0976 1949-0984 |
| language | English |
| publishDate | 2022-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Gut Microbes |
| spelling | doaj-art-d674ccc8e4d94b728aca0f13fbb8188c2025-08-20T03:05:24ZengTaylor & Francis GroupGut Microbes1949-09761949-09842022-12-0114110.1080/19490976.2022.2117508The clinical evidence for postbiotics as microbial therapeuticsAlexis Mosca0Ana Teresa Abreu Y Abreu1Kok Ann Gwee2Gianluca Ianiro3Jan Tack4Thi Viet Ha Nguyen5Colin Hill6Pediatric Gastroenterology and Nutrition Department, APHP Robert Debré, Paris, FranceGastroenterologist and Neuro-gastroenterologist, Angeles del Pedregal Hospital, Mexico City, MexicoDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore and Gleneagles Hospital, SingaporeGastroenterology Unit, Fondazione Policlinico Universitario”A. Gemelli” IRCCS, Rome, ItalyDepartment of Gastroenterology, University Hospitals Leuven, BelgiumDepartment of Gastroenterology, National Children’s Hospital, VietnamAPC Microbiome Institute, University College Cork, IrelandAn optimally operating microbiome supports protective, metabolic, and immune functions, but disruptions produce metabolites and toxins which can be involved in many conditions. Probiotics have the potential to manage these. However, their use in vulnerable people is linked to possible safety concerns and maintaining their viability is difficult. Interest in postbiotics is therefore increasing. Postbiotics contain inactivated microbial cells or cell components, thus are more stable and exert similar health benefits to probiotics. To review the evidence for the clinical benefits of postbiotics in highly prevalent conditions and consider future potential areas of benefit. There is growing evidence revealing the diverse clinical benefits of postbiotics in many prevalent conditions. Postbiotics could offer a novel therapeutic approach and may be a safer alternative to probiotics. Establishing interaction mechanisms between postbiotics and commensal microorganisms will improve the understanding of potential clinical benefits and may lead to targeted postbiotic therapy.https://www.tandfonline.com/doi/10.1080/19490976.2022.2117508Microbiotapostbioticsmicrobial therapeuticsclinical benefitsgastrointestinal disordersallergy |
| spellingShingle | Alexis Mosca Ana Teresa Abreu Y Abreu Kok Ann Gwee Gianluca Ianiro Jan Tack Thi Viet Ha Nguyen Colin Hill The clinical evidence for postbiotics as microbial therapeutics Gut Microbes Microbiota postbiotics microbial therapeutics clinical benefits gastrointestinal disorders allergy |
| title | The clinical evidence for postbiotics as microbial therapeutics |
| title_full | The clinical evidence for postbiotics as microbial therapeutics |
| title_fullStr | The clinical evidence for postbiotics as microbial therapeutics |
| title_full_unstemmed | The clinical evidence for postbiotics as microbial therapeutics |
| title_short | The clinical evidence for postbiotics as microbial therapeutics |
| title_sort | clinical evidence for postbiotics as microbial therapeutics |
| topic | Microbiota postbiotics microbial therapeutics clinical benefits gastrointestinal disorders allergy |
| url | https://www.tandfonline.com/doi/10.1080/19490976.2022.2117508 |
| work_keys_str_mv | AT alexismosca theclinicalevidenceforpostbioticsasmicrobialtherapeutics AT anateresaabreuyabreu theclinicalevidenceforpostbioticsasmicrobialtherapeutics AT kokanngwee theclinicalevidenceforpostbioticsasmicrobialtherapeutics AT gianlucaianiro theclinicalevidenceforpostbioticsasmicrobialtherapeutics AT jantack theclinicalevidenceforpostbioticsasmicrobialtherapeutics AT thiviethanguyen theclinicalevidenceforpostbioticsasmicrobialtherapeutics AT colinhill theclinicalevidenceforpostbioticsasmicrobialtherapeutics AT alexismosca clinicalevidenceforpostbioticsasmicrobialtherapeutics AT anateresaabreuyabreu clinicalevidenceforpostbioticsasmicrobialtherapeutics AT kokanngwee clinicalevidenceforpostbioticsasmicrobialtherapeutics AT gianlucaianiro clinicalevidenceforpostbioticsasmicrobialtherapeutics AT jantack clinicalevidenceforpostbioticsasmicrobialtherapeutics AT thiviethanguyen clinicalevidenceforpostbioticsasmicrobialtherapeutics AT colinhill clinicalevidenceforpostbioticsasmicrobialtherapeutics |